US FDA officials appear most comfortable applying “real-world evidence” to the challenges of patient selection for clinical trials – rather than jumping ahead to using those data sources as a basis for a drug approval decision.
During a week of workshops focused on the theme of real-world evidence in mid-September, FDA officials repeatedly made the point that the agency can, does and will use real-world evidence...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?